Version 1
: Received: 21 July 2023 / Approved: 21 July 2023 / Online: 25 July 2023 (10:21:55 CEST)
How to cite:
Bikbaeva, G.; Kovalskaya, A.; Rodin, A.; Pavlova, T.; Duplyakov, D. Detection and Stabilization of Vulnerable Plaques in the Coronary Arteries. Preprints2023, 2023071557. https://doi.org/10.20944/preprints202307.1557.v1
Bikbaeva, G.; Kovalskaya, A.; Rodin, A.; Pavlova, T.; Duplyakov, D. Detection and Stabilization of Vulnerable Plaques in the Coronary Arteries. Preprints 2023, 2023071557. https://doi.org/10.20944/preprints202307.1557.v1
Bikbaeva, G.; Kovalskaya, A.; Rodin, A.; Pavlova, T.; Duplyakov, D. Detection and Stabilization of Vulnerable Plaques in the Coronary Arteries. Preprints2023, 2023071557. https://doi.org/10.20944/preprints202307.1557.v1
APA Style
Bikbaeva, G., Kovalskaya, A., Rodin, A., Pavlova, T., & Duplyakov, D. (2023). Detection and Stabilization of Vulnerable Plaques in the Coronary Arteries. Preprints. https://doi.org/10.20944/preprints202307.1557.v1
Chicago/Turabian Style
Bikbaeva, G., Tatyana Pavlova and Dmitry Duplyakov. 2023 "Detection and Stabilization of Vulnerable Plaques in the Coronary Arteries" Preprints. https://doi.org/10.20944/preprints202307.1557.v1
Abstract
Background: Atherosclerotic plaque (AP) vulnerability can be assessed by coronary artery imaging techniques. Modern lipid-lowering therapy (LLT) has a stabilizing effect on the AP and reduces the likelihood of progression of vascular remodeling.
Methods: Databases searched comprised PubMed, and the Web of Science up to April 2023. In total, 8 relevant articles were selected, and all of them are original clinical studies.
Results Based on the results of ODISSEY-J-IVUS, there was a decrease in the percentage change in the normalized total volume of AP by 3.1% in the monotherapy group and by 4.8% in the combined LLT group (p = 0.23). According to GLACOV study normalized total atheroma volume decreased by 0.9 mm3 in the placebo group and by 5.8 mm3 in the evolocumab group (95% CI -7.3 -2.5; p<0.001). Plaque regression was observed in 64.3% of patients receiving evolocumab versus 47.3% of those on placebo. The dynamics of the minimum thickness of the fibrous cap varied within 18.0-62.67 microns while on combined LLT and 13.2-33.19 microns on monotherapy (PACMAN-AMI, Gao F). In the HUYGENS study, a lipid arc regression of 57.5° was obtained on combined LLT and by 31.4° with the statin alone.
Conclusion: significant progress in the development of cardiovascular imaging has made it possible to expand our understanding of the morphology of AP, the features of coronary vessel remodeling, and the development of acute cardiovascular complications.
Medicine and Pharmacology, Cardiac and Cardiovascular Systems
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
